<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20110528006617N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-11</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of oral Clonidine and Tranexamic on blood loss during surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the effect of oral Clonidine and Tranexamic acid before Surgery on blood loss in lumbar spine surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/45432</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: First with attention to the number of groups(3 groups)and the number of persons in every group, explained an amount of six block. So all of the situations that six person can stay on that block and stay on the study in form of couple in one of the triple group. After that randomized selection of the block with table of accidental numbers in fifteen times between all of the form in arrangement have done and fifteen blocks an amount of six selected, that allocated to every group two persons, Blinding description: We produced Placebo Capsule similar to Tranexamic Acid and Placebo tablets similar to Clonidine. The Tranexamic Acid group received 2 Capsules of Tranexamic Acid and one tablet of Placebo 2 hours before surgery, the Clonidine  group  received 2 Capsules of Placebo and one tablett of Clonidine 2 hours before surgery, the Placebo group  received 2 Capsules of Placebo and one tablett of Placebo 2 hours before surgery. So the patients do not have any information about the intervention and the person who registered the information do not know which patient in which group ist and the study has three blind side.</study_design>
      <phase>3</phase>
      <hc_freetext>General anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The first intervention group(Tranexamic acid) receive 600mg oral Tranexamic acid and one placebo tablet 2 hour before surgery. Induction of anesthesia with 0/05mg/kg Midazolam, 3 microgram/Kg Fentanil, 2 mg/kg Propofol, 2mg/kg Lidocaine,Cisatracuriom 0/15 mg/kg and maintenance of anesthesia during the surgery is with 100microgram/kg/min Propofol and for induced of controlled hypotension infusion of 0/1-1 microgram/kg/min by goal of MAP(80-85mmHg). Intervention 2: Intervention group: The second intervention group(Clonidine) receive 0/2 mg tablet of Clonidine and 2 Capsules of placebo 2 hours before surgery. Induction of anesthesia with 0/05mg/kg Midazolam, 3 microgram/Kg Fentanil, 2 mg/kg Propofol, 2mg/kg Lidocaine,Cisatracuriom 0/15 mg/kg and maintenance of anesthesia during the surgery is with 100microgram/kg/min Propofol and for induced of controlled hypotension infusion of 0/1-1 microgram/kg/min by goal of MAP(80-85mmHg). Intervention 3: Control group: The second intervention group(Placebo) receive one tablet of Placebo and 2 Capsules of placebo 2 hours before surgery. Induction of anesthesia with 0/05mg/kg Midazolam, 3 microgram/Kg Fentanil, 2 mg/kg Propofol, 2mg/kg Lidocaine,Cisatracuriom 0/15 mg/kg and maintenance of anesthesia during the surgery is with 100microgram/kg/min Propofol and for induced of controlled hypotension infusion of 0/1-1 microgram/kg/min by goal of MAP(80-85mmHg).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No further Information is available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehrdad Masoudifar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alzahra Hospital, Sofe Blvd, Shahid Keshvari highway</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174675731</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>Masoudifar@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehrdad Masoudifar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alzahra hospital, Sofe Blvd, Shahid Keshvari highway</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174675731</zip>
        <telephone>0098 31 362020202</telephone>
        <email>Masoudifar@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 20 – 65 year
patients who consent to the informed consent to participate in the study
ASA class 1 ,2</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Beta blocker and Calcium blocker usage
sedative drugs usage
Opioids usage
addiction to Alcohol
allergic reaction to drugs
allergic reaction to Local anesthetic drugs
history of lumbar surgery
risk factor of thrombosis
anticoagulants drugs usage
Digoxin usage
Aspirin uage</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M51.06</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Intervertebral disc disorders with myelopathy, lumbar region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The first intervention group(Tranexamic acid) receive 600mg oral Tranexamic acid and one placebo tablet 2 hour before surgery. Induction of anesthesia with 0/05mg/kg Midazolam, 3 microgram/Kg Fentanil, 2 mg/kg Propofol, 2mg/kg Lidocaine,Cisatracuriom 0/15 mg/kg and maintenance of anesthesia during the surgery is with 100microgram/kg/min Propofol and for induced of controlled hypotension infusion of 0/1-1 microgram/kg/min by goal of MAP(80-85mmHg)</i_keyword>
      <i_keyword>Intervention group: The second intervention group(Clonidine) receive 0/2 mg tablet of Clonidine and 2 Capsules of placebo 2 hours before surgery. Induction of anesthesia with 0/05mg/kg Midazolam, 3 microgram/Kg Fentanil, 2 mg/kg Propofol, 2mg/kg Lidocaine,Cisatracuriom 0/15 mg/kg and maintenance of anesthesia during the surgery is with 100microgram/kg/min Propofol and for induced of controlled hypotension infusion of 0/1-1 microgram/kg/min by goal of MAP(80-85mmHg)</i_keyword>
      <i_keyword>Control group: The second intervention group(Placebo) receive one tablet of Placebo and 2 Capsules of placebo 2 hours before surgery. Induction of anesthesia with 0/05mg/kg Midazolam, 3 microgram/Kg Fentanil, 2 mg/kg Propofol, 2mg/kg Lidocaine,Cisatracuriom 0/15 mg/kg and maintenance of anesthesia during the surgery is with 100microgram/kg/min Propofol and for induced of controlled hypotension infusion of 0/1-1 microgram/kg/min by goal of MAP(80-85mmHg)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic Blood Pressure. Timepoint: Basic time(two hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, every 15 min during surgery, in the time of patient enter to the recovery. Method of measurement: mmHg , SAADAT Sphygmomanometer monitoring.</prim_outcome>
      <prim_outcome>Diastolic Blood Pressure. Timepoint: Basic time(two hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, every 15 min during surgery, in the time of patient enter to the recovery. Method of measurement: mmHg , SAADAT Sphygmomanometer monitoring.</prim_outcome>
      <prim_outcome>Mean Artherial Pressure. Timepoint: Basic time(two hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, every 15 min during surgery, in the time of patient enter to the recovery. Method of measurement: mmHg , SAADAT Sphygmomanometer monitoring.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: Basic time(two hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, every 15 min during surgery, in the time of patient enter to the recovery. Method of measurement: beat/min , SAADAT ECG monitoring.</prim_outcome>
      <prim_outcome>Volume Of Blood Loss. Timepoint: enter to the recovery, export from recovery. Method of measurement: Milliliter,volume of blood in the suction, Bloody gas.</prim_outcome>
      <prim_outcome>Surgeon Satisfaction. Timepoint: End of the surgery. Method of measurement: Likert Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Hypotension. Timepoint: Basic time(two hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, every 15 min during surgery, in the time of patient enter to the recovery. Method of measurement: mmHg, SAADAT Sphygmomanometer monitor.</sec_outcome>
      <sec_outcome>Hypertension. Timepoint: Basic time(two hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, every 15 min during surgery, in the time of patient enter to the recovery. Method of measurement: mmHg, SAADAT Sphygmomanometer monitor.</sec_outcome>
      <sec_outcome>Tachycardia. Timepoint: Basic time(two hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, every 15 min during surgery, in the time of patient enter to the recovery. Method of measurement: beat/min ,SAADAT ECG monitoring.</sec_outcome>
      <sec_outcome>Bradycardia. Timepoint: Basic time(two hours before surgery), before anesthesia induction, 1,3,5,10,15 min after anesthesia, every 15 min during surgery, in the time of patient enter to the recovery. Method of measurement: beat/min ,SAADAT ECG monitoring.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-06-22</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical sciences</contact_name>
        <contact_address>Isfahan University Of Medical Science, Hezar Jarib Ave Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
